nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2008 | Original Article

The potential of ²¹¹Astatine for NIS-mediated radionuclide therapy in prostate cancer

verfasst von: Michael J. Willhauck, Bibi-Rana Sharif Samani, Ingo Wolf, Reingard Senekowitsch-Schmidtke, Hans-Jürgen Stark, Geerd J. Meyer, Wolfram H. Knapp, Burkhard Göke, John C. Morris, Christine Spitzweg

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We reported recently the induction of selective iodide uptake in prostate cancer cells (LNCaP) by prostate-specific antigen (PSA) promoter-directed sodium iodide symporter (NIS) expression that allowed a significant therapeutic effect of ¹³¹I. In the current study, we studied the potential of the high-energy alpha-emitter ²¹¹At, also transported by NIS, as an alternative radionuclide after NIS gene transfer in tumors with limited therapeutic efficacy of ¹³¹I due to rapid iodide efflux.

Methods

We investigated uptake and therapeutic efficacy of ²¹¹At in LNCaP cells stably expressing NIS under the control of the PSA promoter (NP-1) in vitro and in vivo.

Results

NP-1 cells concentrated ²¹¹At in a perchlorate-sensitive manner, which allowed a dramatic therapeutic effect in vitro. After intrapertoneal injection of ²¹¹At (1 MBq), NP-1 tumors accumulated approximately 16% ID/g ²¹¹At (effective half-life 4.6 h), which resulted in a tumor-absorbed dose of 1,580 ± 345 mGy/MBq and a significant tumor volume reduction of up to 82 ± 19%, while control tumors continued their growth exponentially.

Conclusions

A significant therapeutic effect of ²¹¹At has been demonstrated in prostate cancer after PSA promoter-directed NIS gene transfer in vitro and in vivo suggesting a potential role for ²¹¹At as an attractive alternative radioisotope for NIS-targeted radionuclide therapy, in particular in smaller tumors with limited radionuclide retention time.

Stearns ME, McGarvey T. Prostate cancer: therapeutic, diagnostic, and basic studies. Lab Invest. 1992;67(5):540–52.PubMed

Harrington KJ, Spitzweg C, Bateman AR, Morris JC, Vile RG. Gene therapy for prostate cancer: current status and future prospects. J Urol. 2001;166:1220–33.PubMedCrossRef

Mazzaferri EL. Carcinoma of follicular epithelium: Radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD, editors. The thyroid: a fundamental and clinical text. 7th ed. Philadelphia: Lippincott-Raven; 1996. p. 922–45.

Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458–60.PubMedCrossRef

Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC. Clinical review 132: The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab. 2001;86(7):3327–35.PubMedCrossRef

Spitzweg C, O’Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000;60:6526–30.PubMed

Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver BD, Heufelder AE, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999;59:2136–41.PubMed

Spitzweg C, Scholz IV, Bergert ER, Tindall DJ, Young CY, Göke B, et al. Retinoic acid-induced stimulation of sodium iodide symporter (NIS) expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology. 2003;144:3423–32.PubMedCrossRef

Scholz IV, Cengic N, Goke B, Morris JC, Spitzweg C. Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. J Clin Endocrinol Metab. 2004;89(3):1108–16.PubMedCrossRef

10.

Spitzweg C, Dietz AB, O’Connor MK, Bergert ER, Tindall DJ, Young CY, et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001;8(20):1524–31.PubMedCrossRef

11.

Dwyer RM, Schatz SM, Bergert ER, Myers RM, Harvey ME, Classic KL, et al. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther. 2005;12(5):835–41.PubMedCrossRef

12.

Haberkorn U, Kinscherf R, Kissel M, Kübler W, Mahmut M, Sieger S, et al. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther. 2003;10:774–80.PubMedCrossRef

13.

Carlin S, Cunningham SH, Boyd M, McCluskey AG, Mairs RJ. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Therapy. 2000;7:1529–36.PubMedCrossRef

14.

Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol. 2002;57:559–74.CrossRef

15.

Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Potter E. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging. 2002;29(7):842–54.PubMedCrossRef

16.

Carlin S, Akabani G, Zalutsky MR. In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J Nucl Med. 2003;44(11):1827–38.PubMed

17.

Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocrine Rev. 2003;24(1):48–77.CrossRef

18.

Van Sande J, Massart C, Beauwens R, Schoutens A, Costagliola S, Dumont JE, et al. Anion selectivity by the sodium iodide symporter. Endocrinology. 2003;144(1):247–52.PubMedCrossRef

19.

Zalutsky MR. Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med. 2005;46(Suppl 1):151S–6S.PubMed

20.

Helmekea HJ, Mahnke E, Schaardt U, Knapp WH. External targets for the production of 211At—review and status of the target development at the Hannover cyclotron. Z Med Phys. 2004;14(3):195–9.PubMed

21.

Weiss SJ, Philp NJ, Grollman EF. Iodine transport in a continuous line of cultured cells from rat thyroid. Endocrinology. 1984;114:1090–8.PubMedCrossRef

22.

Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999;59(3):661–8.PubMed

23.

Willhauck MJ, Samani BR, Gildehaus FJ, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, et al. Application of ¹⁸⁸Re as an alternative radionuclide for treatment of prostate cancer following tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab. 2007;92:4451–8.PubMedCrossRef

24.

Cengic N, Baker CH, Schutz M, Goke B, Morris JC, Spitzweg C. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab. 2005;90(8):4457–64.PubMedCrossRef

25.

Dwyer RM, Bergert ER, O’Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res. 2005;11:1483–9.PubMedCrossRef

26.

Dwyer RM, Bergert ER, O’Connor MK, Gendler SJ, Morris JC. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther. 2006;17(6):661–8.PubMedCrossRef

27.

Dwyer RM, Bergert ER, O’Connor MK, Gendler SJ, Morris JC. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther. 2006;13(1):60–6.PubMedCrossRef

28.

Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res. 2003;63(22):7840–4.PubMed

29.

Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther. 2005;12(3):272–80.PubMedCrossRef

30.

Spitzweg C, Baker C, Bergert ER, O’Connor MK, Morris JC. Image-guided radioiodide therapy of medullary thyroid cancer following carcinoembryonic antigen (CEA)-promoter-targeted sodium iodide symporter (NIS) gene expression. Hum Gene Ther. 2007;18(10):916–24.PubMedCrossRef

31.

Dingli D, Diaz RM, Bergert ER, O’Connor MK, Morris JC, Russell SJ. Genetically targeted radiotherapy for multiple myeloma. Blood. 2003;102:489–96.PubMedCrossRef

32.

Sieger S, Jiang S, Schönsiegel F, Eskerski H, Kübler W, Altmann A, et al. Tumor-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur J Nucl Med Mol Imaging. 2003;30(5):748–56.PubMed

33.

Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, et al. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med. 2001;42:317–25.PubMed

34.

Smit JW, Schroder-Van der Elst JP, Karperien M, Que I, Stokkel M, van der Heide D, et al. Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab. 2002;87(3):1247–53.PubMedCrossRef

35.

Shimura H, Haraguchi K, Myazaki A, Endo T, Onaya T. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I− symporter gene. Endocrinology. 1997;138(10):4493–6.PubMedCrossRef

36.

Petrich T, Quintanilla-Martinez L, Korkmaz Z, Samson E, Helmeke HJ, Meyer GJ, et al. Effective cancer therapy with the a-particle emitter [211-At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin Cancer Res. 2006;12(4):1342–8.PubMedCrossRef

37.

Carlin S, Mairs RJ, Welsh P, Zalutsky MR. Sodium-iodide symporter (NIS)-mediated accumulation of (211At)astatide in NIS-transfected human cancer cells. Nucl Med Biol. 2002;29:729–39.PubMedCrossRef

38.

Lindencrona U, Nilsson M, Forssell-Aronsson E. Similarities and differences between free 211At and 125I-transport in porcine thyroid epithelial cells cultured in bicameral chambers. Nucl Med Biol. 2001;28(1):41–50.PubMedCrossRef

39.

Kampf G. Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol Radiother (Berl). 1988;29(6):631–58.

40.

Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000;6:871–8.PubMedCrossRef

41.

Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE. Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab. 1999;84(11):4178–84.PubMedCrossRef

42.

Wapnir IL, Goris M, Yudd A, Dohan O, Adelman D, Nowels K, et al. The Na+/I− symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 2004;10:4294–302.PubMedCrossRef

43.

McLendon RE, Archer GE, Garg PK, Bigner DD, Zalutsky MR. Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. Int J Radiat Oncol Biol Phys. 1996;35(1):69–80.PubMed

44.

Behr M, Schmitt TL, Espinoza CR, Loos U. Cloning of a functional promoter of the human sodium/iodide symporter gene. Biochem J. 1998;331:359–63.PubMed

45.

Back T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, et al. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. J Nucl Med. 2005;46(12):2061–7.PubMed

46.

Russ V, Elfberg H, Thoma C, Kloeckner J, Ogris M, Wagner E. Novel degradable oligoethylenimine acrylate ester-based pseudodendrimers for in vitro and in vivo gene transfer. Gene Ther. 2008;15(1):18–29.PubMedCrossRef

Titel: The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer
verfasst von: Michael J. Willhauck
Bibi-Rana Sharif Samani
Ingo Wolf
Reingard Senekowitsch-Schmidtke
Hans-Jürgen Stark
Geerd J. Meyer
Wolfram H. Knapp
Burkhard Göke
John C. Morris
Christine Spitzweg
Publikationsdatum: 01.07.2008
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0775-4

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The potential of ²¹¹Astatine for NIS-mediated radionuclide therapy in prostate cancer

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2008

Could 99mTc-glucarate be used to evaluate tumour necrosis?

Something old, something new, PET in adrenal imaging

Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG PET study

Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT

Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective

The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI